Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo

被引:217
作者
Ringshausen, Ingo
O'Shea, Cloclagh C.
Finch, Andrew J.
Swigart, Lamorna Brown
Evan, Gerard I.
机构
[1] Univ Calif San Francisco, Canc Res Inst, Ctr Comprehens Canc, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, Ctr Comprehens Canc, San Francisco, CA 94143 USA
关键词
D O I
10.1016/j.ccr.2006.10.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There is currently much interest in the idea of restoring p53 activity in tumor cells by inhibiting Hdm2/Mdm2. However, it has remained unclear whether this would also activate p53 in normal cells. Using a switchable enclogenous p53 mouse model, which allows rapid and reversible toggling of p53 status between wild-type and null states, we show that p53 is spontaneously active in all tested tissues of mdm2-deficient mice, triggering fatal pathologies that include ablation of classically radiosensitive tissues. In apoptosis-resistant tissues, spontaneous unbuffered p53 activity triggers profound inhibition of cell proliferation. Such acute spontaneous p53 activity occurs in the absence of any detectable p53 posttranslational modification, DNA damage, or p19(ARF) signaling and triggers rapid p53 degradation.
引用
收藏
页码:501 / 514
页数:14
相关论文
共 59 条
[31]  
LUNA RMD, 1995, NATURE, V378, P203
[32]   A second p53 binding site in the central domain of mdm2 is essential for p53 ubiquitination [J].
Ma, Jianhong ;
Martin, John D. ;
Zhang, Hong ;
Auger, Kurt R. ;
Ho, Thau F. ;
Kirkpatrick, Robert B. ;
Grooms, Michael H. ;
Johanson, Kyung O. ;
Tummino, Peter J. ;
Copeland, Robert A. ;
Lai, Zhihong .
BIOCHEMISTRY, 2006, 45 (30) :9238-9245
[33]   Mdmx as an essential regulator of p53 activity [J].
Marine, JC ;
Jochemsen, AG .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 331 (03) :750-760
[34]   mdm2 is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation [J].
Mendrysa, SM ;
McElwee, MK ;
Michalowski, J ;
O'Leary, KA ;
Young, KM ;
Perry, ME .
MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (02) :462-473
[35]   Tumor suppression and normal aging in mice with constitutively high p53 activity [J].
Mendrysa, SM ;
O'Leary, KA ;
McElwee, MK ;
Michalowski, J ;
Eisenman, RN ;
Powell, DA ;
Perry, ME .
GENES & DEVELOPMENT, 2006, 20 (01) :16-21
[36]   THE MDM-2 ONCOGENE PRODUCT FORMS A COMPLEX WITH THE P53 PROTEIN AND INHIBITS P53-MEDIATED TRANSACTIVATION [J].
MOMAND, J ;
ZAMBETTI, GP ;
OLSON, DC ;
GEORGE, D ;
LEVINE, AJ .
CELL, 1992, 69 (07) :1237-1245
[37]   Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53 [J].
Parant, J ;
Chavez-Reyes, A ;
Little, NA ;
Yan, W ;
Reinke, V ;
Jochemsen, AG ;
Lozano, G .
NATURE GENETICS, 2001, 29 (01) :92-95
[38]   Understanding the genotoxicity of tamoxifen? [J].
Phillips, DH .
CARCINOGENESIS, 2001, 22 (06) :839-849
[39]   Gene-specific mechanisms of p53 transcriptional control and prospects for cancer therapy [J].
Resnick-Silverman, Lois ;
Manfredi, James J. .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2006, 99 (03) :679-689
[40]   The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53 [J].
Robertson, KD ;
Jones, PA .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (11) :6457-6473